PharmaZell gladly informs that we have received US-FDAs approval for our DMF-Type-II for our Product Teriflunomide.
The construction of our new buildings in gropello continues apace.
We are pleased to announce that PharmaZell(India)Private Limited has been awarded EcoVadis Silver Medal in Recognition for Sustainability Performance. This Recognition places our company among the top 25 percent of companies assessed by EcoVadis.
New expansion of fully automated and dedicated Production facility for Mesalamine has picked up its momentum at Visakhapatnam site. It is targeted to start the production in October-2021. Impact of COVID-19 lead to few disturbances for 2-3 weeks, however there are adeuqate buffer time in plan to mitigate potential delays. Majority of the equipment are
20 April 2021, the PharmaZell Group one on Europe’s leading manufacturer of active ingredients, is pleased to announce its production site FarmaBios SpA (in Gropello/Italy) has received validation from the European Commission (“EC”), and European Food Safety Authority (“EFSA”) for the dossier on synthetic CBD as a Novel Food.
We are pleased to announce that the activities on synthetic CBD at our Farmabios site are progressing smoothly. The API is produced at a commercial batch size using a THC-free route, allowing us to satisfy high customer demands. As extension to the existing EU- and US-DMF for our pharmaceutical grade CBD, a Novel Food dossier
FarmaBios successfully completed the certification process in accordance with the ISO 45001:2018 standards. The new certificate is the last achievement of the list together with ISO 9001:2015 and ISO 14001:2015. With this certificate valid until 28th July 2023, FarmaBios presents objective evidence for the commitment to provide high quality and to works on continuous improvement